跳至主要内容
临床试验/NCT05517512
NCT05517512已完成不适用

Low Serum Pregnancy Protein 13 Early in Pregnancy Might Predict the Oncoming Gestational Hypertensive Disorders, Especially Early-onset Preeclampsia

Benha University1 个研究点 分布在 1 个国家目标入组 138 人开始时间: 2020年3月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
138
试验地点
1
主要终点
Serum biomarkers and GHD

研究概览

简要总结

the attendants of the clinic with a one-missed period (T0) underwent determination of baseline blood pressure (BP) measures and gave blood samples for estimation of levels of placental growth factor (PLGF), soluble fms-like tyrosine kinase-1 (sFlt-1) and pregnancy protein 13 (PP13). The same evaluation was repeated on the 6th, 24th, 32nd, and 36th gestational week (GW). Twenty non-pregnant women gave samples as a negative control group.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
21 Years 至 33 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Normotensive women who attended the clinic with a one-missed period (T0)

排除标准

  • History of essential hypertension (HTN)
  • renal diseases
  • hepatic diseases
  • cardiac diseases
  • metabolic syndrome
  • body mass index (BMI) >35 kg/ m2
  • congenital heart diseases

结局指标

主要结局

Serum biomarkers and GHD

时间窗: 9 months

The primary outcome is the ability of early ELISA estimation of biomarkers for prediction of GHD

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Amr Sharaf Eldein

Assistant professor of gynecology

Benha University

研究点 (1)

Loading locations...

相似试验